Current Possibilities of Infantile Haemangioma Treatment
Authors:
V. Novotná 1; A. Kováčiková Curková 1; M. Šimaljaková 1; C. Gelmetti 2
Authors place of work:
Dermatovenerologická klinika LF UK a UN Bratislava, Slovenská republika
prednosta prof. MUDr. Mária Šimaljaková, PhD.
1; Department of Dermatology, University of Milan, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico
Milan, Italy, prednosta prof. Carlo Gelmetti, MD, PhD.
2
Published in the journal:
Čes-slov Derm, 88, 2013, No. 2, p. 79-82
Category:
Pharmacologyand Therapy, Clinical Trials
Summary
Propranolol as a pharmacological treatment of infantile haemangioma (IH) was first reported in 2008 and since then has become popular worldwide with positive clinical results and rare adverse events. IH became a new indication group for propranolol. Authors report a case of a 3-month-old child with a large infantile haemangioma of the face treated successfully with propranolol. In the submitted paper the recent knowledge about treatment of large IH with propranolol is reported, the probable mechanism of action and success of this treatment is documented in the case study.
Key words:
infantile hemangioma – pharmacological treatment – propranolol
Zdroje
1. CAMBIAGHI, C., GELMETTI, C. Novita in dermatologia pediatrica. Prospettive in pediatria, 2007, 37, p. 123–152.
2. De GRAAF, M., BREUR, M. J., RAPHAEL, M. F., VOS, M., BREUMGEM, C. C., PASMANS, S. G. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J. Am. Acad. Dermatol., 2011, 65, p. 320–327.
3. EICHENFIELD, L. F., FRIEDEN, I. J., ESTERLY, N. B. Textbook of neonatal dermatology. W. B. Saunders Company, Philadelphia, USA, 2001, p. 324–334.
4. FABEROVA, R., BUČKOVÁ, H., FEIT, J. Hemangiomy u dětí. Čes-slov Derm., 2002, 4, s. 178–182.
5. GELMETTI, C. Diagnosi e terapia degli angiomi infantili. Prospettive in pediatria, 2001, 31, s. 287–295.
6. GREENBERGER, S., BISCHOFF, J. Infantile hemangioma – mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Prospect Med., 2011, 1.
7. LANDTHALER, M., HOHENLEUNTNER, U. Zur klassifikation vascularer fehl- und neubildingen. Hautartz, 1997, 48, s. 622–628.
8. LÉAUTÉ-LABRťZE, C., DUMAS DE LA ROQUE, E., HUBICHE, T., BORALEVI, F., THAMBO, J. B., TAžEB, A. Propranolol for severe hemangiomas of infancy. Eng. J. Med., 2008, 358, 24, p. 2649–2651.
9. MOEHRLE, M., LÉAUTÉ-LABRťZE, C., SCHMIDT, V., ROCKEN, M., POETS, C. F., GOELZ, R. Topical Timolol for small hemangiomas of infancy. Pediatr Dermatol., 2012, doi: 10.1111/j.1525-1470.2012.01723.x
10. PRASBANTH, G. P. How ęunsafeę is propranolol when used in the treatment of infantile hemangioma? J. Am. Acad. Dermatol., 2012, 66, 5, p. 854–855.
Štítky
Dermatology & STDs Paediatric dermatology & STDsČlánok vyšiel v časopise
Czech-Slovak Dermatology
2013 Číslo 2
Najčítanejšie v tomto čísle
- Current Possibilities of Infantile Haemangioma Treatment
- Psoriasis in Children
- Trends in the Development of Contact Sensitivity to Selected Additives of Pharmaceutical and Cosmetic Products in the Czech Republic